Sorafenib (BAY 43-9006) to Treat Children With Solid Tumors or Leukemias
|ClinicalTrials.gov Identifier: NCT01445080|
Recruitment Status : Completed
First Posted : October 3, 2011
Last Update Posted : August 7, 2017
National Cancer Institute (NCI)
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Completed|
|Actual Primary Completion Date :||June 14, 2012|
|Actual Study Completion Date :||June 14, 2012|
Reuter CW, Morgan MA, Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood. 2000 Sep 1;96(5):1655-69. Review.
Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta. 2003 Jun 5;1653(1):25-40. Review.